Editorially independent content, supported with advertising
03.21.25
What are the real-world safety data following administration of faricimab (Vabysmo, Genentech)? Maura Di Nicola, MD, and guests Sruthi Arepalli, MD, and Barton Blackorby, MD, review data from a real-world, single-center, retrospective study of approximately 4500 injections of faricimab in over 700 patients at Wills Eye Hospital. What did the data show? And do these data effect the clinical patterns of Drs. Di Nicola, Arepalli, and Blackorby?
07.18.25
Diabetic Retinopathy Severity and Income StatusBen Young, MD; Phoebe Mellen, MD; and Jordan Deaner, MD
06.20.25
Photobiomodulation for Age-related Macular DegenerationModerator Barton Blackorby, MD; Hong-Uyen Hua, MD; and Louis Cai, MD
03.21.25
Rates of Ocular AEs After Faricimab InjectionMaura Di Nicola, MD; Sruthi Arepalli, MD; and Barton Blackorby, MD
12.19.24
Switching from Aflibercept to Faricimab in Wet AMD PatientsBen Young, MD, MS; Lediana Goduni, MD; and Joshua Uhr, MD,
11.21.24
New Retina Radio Journal Club w/ VBS: Does Metformin Reduce AMD Risk?Moderator Rebecca Soares, MD; Matt Starr, MD; and Nikisha Kothari, MD
10.17.24
New Retina Radio Journal Club with VBS: Pre-treatment with Chlorhexidine vs. Povidone-Iodine in Endophthalmitis PreventionMaura Di Nicola, MD; Sruthi Arepalli, MD; and Barton Blackorby, MD
09.17.24
New Retina Radio Journal Club w/ VBS: Risk of Death, Stroke, and MI After RAOKatherine Talcott, MD; Kyle Kovacs, MD; and Phoebe Mellen, MD
08.29.24
New Retina Radio Journal Club with VBS: Switching to Faricimab in Wet AMD Patients With a History of Anti-VEGF TherapyBen Young, MD, MS; Lediana Goduni, MD; and Josh Uhr, MD,
07.19.24
New Retina Radio Journal Club w/ VBS: Risk Factors for Switching from Bevacizumab to Aflibercept in Protocol ACRebecca Soares, MD; Matt Starr, MD; and Nikisha Kothari, MD
Show More